What is the 13F Pro Quality Score for ALGS?

13F Pro ranks Aligos Therapeutics, Inc. (ALGS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ALGS's current score at https://13fpro.ai/company/ALGS (free sign-up required for the full ranking).

Where does 13F Pro source ALGS data?

All Aligos Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Aligos Therapeutics, Inc. files with the SEC under CIK 1799448. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ALGS in?

Aligos Therapeutics, Inc. (ALGS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ALGS research updated on 13F Pro?

ALGS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Aligos Therapeutics, Inc.(ALGS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1799448 ALGS stock profile & AI dashboard →

13F Pro Quality Score

4.6/100

Rank #2,955 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ALGS Scores 5/100

exact factor attribution · 2026-09-11

ALGS's composite is held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

-2.0 pts

11th pct

Shareholder dilution

-2.3 pts

4th pct

Institutional flow

-2.4 pts

3th pct

Earnings quality

-4.3 pts

7th pct

Capital efficiency

-4.4 pts

6th pct

Scale

-6.8 pts

5th pct

Profitability

-6.9 pts

4th pct

Free cash flow

-7.1 pts

3th pct

Revenue growth

-9.3 pts

4th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ALGS Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Aligos Therapeutics, Inc. (ALGS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALGS at 4.6/100 on a 32-signal composite quality model, placing it at rank #2,955 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of ALGS by reported 13-F value include Deep Track Capital, Alyeska Investment Group, L.P., Sio Capital Management, based on the most recent SEC filings. ALGS trades on the Nasdaq exchange and files with the SEC under CIK 1799448. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALGS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aligos Therapeutics, Inc. directly from SEC EDGAR. Aligos Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 4 and 14 since 2025, currently 4.6 — a declining long-term trajectory across 11 quarterly and live scoring snapshots.

Revenue

Q2 2026

$0.00

Net Income

Q2 2026

$-1.5M

ROIC

Q2 2026

-23.7%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-39.5% YoY

$2.2MFY 2025

FY22 $0.00FY23 $6.2MFY24 $3.6MFY25 $2.2M

Net Income

+81.6% YoY

$-24.2MFY 2025

FY22 $-96.0MFY23 $-87.7MFY24 $-131.2MFY25 $-24.2M

Operating Income

+1.3% YoY

$-88.0MFY 2025

FY22 $-97.6MFY23 $-88.1MFY24 $-89.2MFY25 $-88.0M

EPS (Diluted)

+88.3% YoY

$-2.45FY 2025

FY22 $-2.25FY23 $-34.20FY24 $-20.94FY25 $-2.45

Total Assets

+26.3% YoY

$88.5MFY 2025

FY22 $146.7MFY23 $151.5MFY24 $70.1MFY25 $88.5M

Op. Cash Flow

-2.2% YoY

$-82.5MFY 2025

FY22 $-79.4MFY23 $-79.0MFY24 $-80.7MFY25 $-82.5M

Free Cash Flow

—FY 2025

FY22 $-80.3MFY23 $-79.0MFY24 $-80.9MFY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.2M -39.5%	$3.6M -41.7%	$6.2M	$0.00	$0.00	$0.00
Net Income	$-24.2M +81.6%	$-131.2M -49.6%	$-87.7M +8.7%	$-96.0M +25.2%	$-128.3M -18.2%	$-108.5M
Operating Income	$-88.0M +1.3%	$-89.2M -1.2%	$-88.1M +9.7%	$-97.6M +24.0%	$-128.3M -31.2%	$-97.8M
EPS (Diluted)	$-2.45 +88.3%	$-20.94 +38.8%	$-34.20 -1420.0%	$-2.25	—	—
Total Assets	$88.5M +26.3%	$70.1M -53.7%	$151.5M +3.3%	$146.7M -37.7%	$235.4M -11.3%	$265.3M
Operating Cash Flow	$-82.5M -2.2%	$-80.7M -2.2%	$-79.0M +0.5%	$-79.4M +31.4%	$-115.7M -55.7%	$-74.3M
Free Cash Flow	—	$-80.9M -2.4%	$-79.0M +1.6%	$-80.3M +31.1%	$-116.6M -52.7%	$-76.3M

Get alerted when ALGS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Aligos Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ALGS

Deep Track Capital, LP
$2.6M444,110 sh
Alyeska Investment Group, L.P.
$2.4M412,000 sh
Sio Capital Management, LLC
$1.9M327,237 sh
MARSHALL WACE, LLP
$1.4M246,579 sh
Woodline Partners LP
$1.0M177,362 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.0M175,543 sh
BAKER BROS. ADVISORS LP
$479.2K83,055 sh
Hillhouse Capital Advisors, Ltd.
$439.9K76,247 sh
D. E. Shaw & Co., Inc.
$383.5K66,463 sh
UBS Group AG
$346.1K59,986 sh

Fund	Value	Shares
Deep Track Capital, LP	$2.6M	444,110
Alyeska Investment Group, L.P.	$2.4M	412,000
Sio Capital Management, LLC	$1.9M	327,237
MARSHALL WACE, LLP	$1.4M	246,579
Woodline Partners LP	$1.0M	177,362
VANGUARD CAPITAL MANAGEMENT LLC	$1.0M	175,543
BAKER BROS. ADVISORS LP	$479.2K	83,055
Hillhouse Capital Advisors, Ltd.	$439.9K	76,247
D. E. Shaw & Co., Inc.	$383.5K	66,463
UBS Group AG	$346.1K	59,986

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ALGS on your watchlist

Track score changes the day Aligos Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ALGS a good stock to buy?

13F Pro's AI-powered analysis of Aligos Therapeutics, Inc. (ALGS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALGS are available on the ALGS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ALGS is classified as a small company.

Which hedge funds own ALGS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALGS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aligos Therapeutics, Inc.'s investment landscape.